Glofitamab
Relapsed or Refractory Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2
—
Rating in progress
Glofitamab in Relapsed or Refractory Aggressive B-cell Lymphoma is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.
Methodology v0.2 · Active